NUCRYST Pharmaceuticals (NCST) Approves Stock Buyback Plan
NUCRYST Pharmaceuticals (Nasdaq: NCST) has authorized a program for the company to repurchase up to 900,000 shares of its outstanding common stock for an amount not to exceed $1.3 million using the facilities of NASDAQ.
NUCRYST Pharmaceuticals Corp. develops, manufactures and commercializes medical products that fight infection and inflammation.[SM]
NUCRYST Pharmaceuticals Corp. develops, manufactures and commercializes medical products that fight infection and inflammation.[SM]
You May Also Be Interested In
- White Mountains (WTM) Approves Additional 1M Common Buyback
- SEI Investments (SEIC) Adds $100M to Buyback
- Riverbed (RVBD) Raises Buyback Program to $300M
Create E-mail Alert Related Categories
Stock BuybacksSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
